| Literature DB >> 28780537 |
Gita Shafiee1, Afshin Ostovar2, Ramin Heshmat1, Hossein Darabi2, Farshad Sharifi3, Alireza Raeisi2, Neda Mehrdad3, Zhaleh Shadman4, Faride Razi4, Mohammad Reza Amini5, Seyed Masoud Arzaghi3, Hamidreza Aghaei Meybodi6, Akbar Soltani5, Iraj Nabipour7, Bagher Larijani5.
Abstract
INTRODUCTION: Musculoskeletal disorders and cognitive diseases are prevalent, and they are significant determinants of morbidity and mortality in older adults. The aim of this study is to investigate the prevalence of musculoskeletal and cognitive diseases and their risk factors and also to assess their associations during future follow-ups. METHODS AND ANALYSIS: Bushehr Elderly Health (BEH) programme is a population-based prospective cohort study being conducted in Bushehr, a southern province of Iran. A total of 3000 older people aged ≥60 years participated in the first stage from which 2772 were eligible to participate in the second stage, which started after 2.5 years. Data including demographic status, lifestyle factors, general healthandmedical history, and mentalandfunctional health are collected through a questionnaire. Anthropometric measures, performance testsandmuscle strength, blood pressure and and body composition measurements are done. A total 25 cc venous blood is taken, and sera are stored at -80°C for possible future analyses. ETHICS AND DISSEMINATION: The study protocol was approved by the ethics committee of Endocrinology and Metabolism Research Institute, affiliated to Tehran University of Medical Science as well as the Research Ethics Committee of Bushehr University of Medical Sciences. A written informed consent was signed by all the participants. The study findings will show the prevalence of musculoskeletal disease, cognitive impairment and their risk factors in an elderly population. The participants will be followed during the study to measure the occurrence outcomes.This study will also have the potential to inform the development of beneficial interventions to improve the management of musculoskeletal and cognitive impairment in Iran and other countries in the Middle East.Our findings will be disseminated via scientific publication as well as presentation to stakeholders, including the patients, clinicians, the public and policymakers, via appropriate avenues. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: cognitive function; elderly; musculoskeletal system; protocol
Mesh:
Year: 2017 PMID: 28780537 PMCID: PMC5577871 DOI: 10.1136/bmjopen-2016-013606
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow chart of enrolments in stage II.
Section and topics of the questionnaire in the Bushehr Elderly Health programme study (stage II)
| Type of data | Parts |
| Demographic data | Personal information |
| National identification number | |
| Age/sex | |
| Marital status | |
| Contact information | |
| Lifestyle factors | Smoking (current and history) |
| Alcohol consumption | |
| Drug abuse | |
| Physical activity | |
| Nutritional assessment | |
| General health and medical history | Quality of life |
| Medical history | |
| Musculoskeletal status (current and history) | |
| Women's health | |
| Mental and functional Health | Cognitive function |
| Depression | |
| Functional assessment | |
| Activities of daily living | |
| Medication use | Administrated by physician |
| Over-the-counter drugs | |
| Supplements |
Laboratory tests of Bushehr Elderly Health programme study (phase II)
| Laboratory tests | Method of measurement |
| CBC | Automated haematology analyser, Medonic CA620 (Menarini Diagnostics Srl, Florence, Italy) |
| Fasting blood sugar | Enzymes (glucose oxidase) colorimetric method using a commercial kit (Pars |
| Lipid profile | Enzymatic (CHOD-PAP) colorimetric method using a commercial kit (Pars Azmun) |
| LDL-C | Enzymatic (CHE& CHO) colorimetric method using a commercial kit (Pars Azmun) |
| HDL-C | Enzymatic (CHE& CHO) colorimetric method using a commercial kit (Pars Azmun) |
| Triglycerides | Enzymatic (GPO-PAP) colorimetric method using a commercial kit (Pars Azmun) |
| Calcium | Enzymatic colorimetric estimation with o-cresolphthalein complex method using a commercial kit (Pars Azmun) |
| Phosphorus | Enzymatic UV method with phosphomolybdate using a commercial kit (Pars Azmun) |
| ALK-p | Photometric method using a commercial kit (Pars Azmun) |
| Urea | Enzymatic (urease) UV method using a commercial kit (Pars Azmun) |
| Creatinin | Jaffe's method, using a Commercial Kit (Pars Azmun) |
| Uric acid | Colorimetry and uricase method using uric acid TOOS kit (Pars Azmun) |
| HbA1C | Boranate affinity method using a CERA-STAT system ( |
ALK-p, alkaline phosphatase; CBC, complete blood count; CHE, cholesterol esterase; CHO, cholesterol oxidase; CHOD-PAP, cholesterol oxidase phenol aminoantipyrine; GPO-PAP, glycerol-3-phosphate oxidase phenol aminoantipyrine; HbA1C, haemoglobin A1C; HDL, high-density lipoprotein; LDL, low-density lipoprotein; UV, ultraviolet.